CA2718943A1 - Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists - Google Patents

Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists Download PDF

Info

Publication number
CA2718943A1
CA2718943A1 CA2718943A CA2718943A CA2718943A1 CA 2718943 A1 CA2718943 A1 CA 2718943A1 CA 2718943 A CA2718943 A CA 2718943A CA 2718943 A CA2718943 A CA 2718943A CA 2718943 A1 CA2718943 A1 CA 2718943A1
Authority
CA
Canada
Prior art keywords
opioid
antagonist
prodrug
opioid agonist
abuse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2718943A
Other languages
English (en)
French (fr)
Inventor
Audra Lynn Stinchcomb
Stan Lee Banks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zynerba Pharmaceuticals Inc
Original Assignee
Alltranz Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alltranz Inc filed Critical Alltranz Inc
Publication of CA2718943A1 publication Critical patent/CA2718943A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2718943A 2008-03-26 2009-03-26 Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists Abandoned CA2718943A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3976308P 2008-03-26 2008-03-26
US61/039,763 2008-03-26
PCT/US2009/038439 WO2009120889A2 (en) 2008-03-26 2009-03-26 Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists

Publications (1)

Publication Number Publication Date
CA2718943A1 true CA2718943A1 (en) 2009-10-01

Family

ID=40809924

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2718943A Abandoned CA2718943A1 (en) 2008-03-26 2009-03-26 Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists

Country Status (6)

Country Link
US (1) US20090246265A1 (enExample)
EP (1) EP2254561A2 (enExample)
JP (1) JP2011515495A (enExample)
CA (1) CA2718943A1 (enExample)
MX (1) MX2010010512A (enExample)
WO (1) WO2009120889A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4458376A4 (en) * 2022-01-30 2025-05-07 Zhejiang University PH-REACTIVE ANALGESIC FOR TARGETING DAMAGED DORSAL ROOT GANGLION SEGMENT AND USE THEREOF

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
MX347741B (es) * 2008-09-16 2017-05-10 Nektar Therapeutics Opioides pegilados con bajo potencial de abuso.
US8386274B1 (en) 2008-09-17 2013-02-26 Mckesson Financial Holdings Limited Systems and methods for a prescription safety network utilizing eligibility verification transactions
EP3064199B1 (en) * 2010-04-02 2023-12-20 Buzzz Pharmaceuticals Limited Abuse-deterrent transdermal formulations of opiate agonists and agonist-antagonists
US8392219B1 (en) 2010-05-10 2013-03-05 Mckesson Financial Holdings Limited Systems and methods for streamlined patient enrollment for one or more healthcare programs
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
GB2481728B (en) * 2010-06-30 2012-05-23 Londonpharma Ltd Formulations and delivery devices for the sublingual administration of opioids
WO2012119151A2 (en) * 2011-03-03 2012-09-07 Saia Mark Stephen Method and apparatus for alcohol administration
US9566341B1 (en) 2011-04-27 2017-02-14 University Of Kentucky Research Foundation Compounds including Cox inhibitor moiety and enhanced delivery of active drugs using same
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
CA2842337C (en) 2011-07-28 2020-02-18 Ian S. Zagon Methods and compositions for treatment of epithelial wounds in diabetic subjects
ES2716570T3 (es) 2012-04-17 2019-06-13 Purdue Pharma Lp Sistemas y procedimientos para tratar o prevenir una respuesta farmacodinámica adversa inducida por opioides
US20140170593A1 (en) * 2012-12-18 2014-06-19 Oltuse, Llc Patch for non-invasive pain relief
US10105487B2 (en) 2013-01-24 2018-10-23 Chrono Therapeutics Inc. Optimized bio-synchronous bioactive agent delivery system
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9867818B2 (en) 2013-09-10 2018-01-16 Insys Development Company, Inc. Sublingual buprenorphine spray
US9918981B2 (en) 2013-09-10 2018-03-20 Insys Development Company, Inc. Liquid buprenorphine formulations
DK3043777T3 (da) 2013-09-10 2020-07-20 Fresh Cut Dev Llc Sublingual buprenorphinspray
US9839611B2 (en) 2013-09-10 2017-12-12 Insys Development Company, Inc. Sublingual buprenorphine spray
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US10722510B2 (en) 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
EP3177146A4 (en) 2014-07-08 2018-01-03 Insys Pharma, Inc. Sublingual naloxone spray
US10617686B2 (en) 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
TW201613590A (en) * 2014-09-12 2016-04-16 Purdue Pharma Lp Systems and methods for attenuating opioid-induced euphoria
US10307381B2 (en) * 2014-10-14 2019-06-04 Hisamitsu Pharmaceutical Co., Inc. Patch
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US10496793B1 (en) 2014-12-15 2019-12-03 Mckesson Corporation Systems and methods for determining eligibility in a prescription safety network program
US10010543B1 (en) 2014-12-23 2018-07-03 Barr Laboratories, Inc. Transdermal dosage form
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
WO2017040607A1 (en) * 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
GB201520390D0 (en) * 2015-11-19 2016-01-06 Euro Celtique Sa Composition
ES2957234T3 (es) * 2016-03-24 2024-01-15 Medrx Co Ltd Preparación de parche con características de prevención del uso incorrecto de sustancias
US20180110730A1 (en) * 2016-10-20 2018-04-26 Axim Biotechnologies, Inc. Chewing gum composition comprising cannabinoids and opioid agonists and/or antagonists
KR102279552B1 (ko) * 2016-12-28 2021-07-19 히사미쓰 세이야꾸 가부시키가이샤 부토르파놀 함유 첩부제
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
JP6704514B2 (ja) 2017-04-25 2020-06-03 久光製薬株式会社 貼付剤
EP3616699B1 (en) 2017-04-25 2021-06-09 Hisamitsu Pharmaceutical Co., Inc. Adhesive patch
JP2020526500A (ja) 2017-06-30 2020-08-31 パーデュー、ファーマ、リミテッド、パートナーシップ 治療方法及びその剤形
EP3703694A4 (en) 2017-11-03 2021-08-18 Nirsum Laboratories, Inc. MEDICINES ANTAGONISTS OF OPIOID RECEPTORS
EP3723725B1 (de) * 2017-12-14 2022-02-02 LTS LOHMANN Therapie-Systeme AG Mikronadelarray aufweisend einen wirkstoff in form von salzen
AU2019279884B2 (en) 2018-05-29 2025-01-30 Morningside Venture Investments Limited Drug delivery methods and systems
US10807995B2 (en) 2018-07-13 2020-10-20 Alkermes Pharma Ireland Limited Thienothiophene compounds for long-acting injectable compositions and related methods
US10799496B2 (en) 2018-07-13 2020-10-13 Alkermes Pharma Ireland Limited Naphthylenyl compounds for long-acting injectable compositions and related methods
US10975099B2 (en) 2018-11-05 2021-04-13 Alkermes Pharma Ireland Limited Thiophene compounds for long-acting injectable compositions and related methods
JP2022507660A (ja) 2018-11-16 2022-01-18 モーニングサイド ベンチャー インベストメンツ リミテッド 温度によって調節される経皮薬剤送達システム
TWI827777B (zh) * 2018-12-27 2024-01-01 昱展新藥生技股份有限公司 納曲酮注射型緩釋製劑
WO2020223894A1 (en) 2019-05-07 2020-11-12 Nirsum Laboratories, Inc. Opioid receptor antagonist prodrugs
WO2023022050A1 (ja) * 2021-08-17 2023-02-23 株式会社カネカ アミノアルキルテトラヒドロピラン誘導体

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966940A (en) * 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
FR2519985A1 (fr) * 1982-01-15 1983-07-22 Ugine Kuhlmann Procede perfectionne de fabrication de l'e-caprolactone
US4780320A (en) * 1986-04-29 1988-10-25 Pharmetrix Corp. Controlled release drug delivery system for the periodontal pocket
US4673679A (en) * 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
US5006342A (en) * 1986-12-22 1991-04-09 Cygnus Corporation Resilient transdermal drug delivery device
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5288502A (en) * 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
US5919473A (en) * 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
US7011843B2 (en) * 1997-10-01 2006-03-14 Lts Lohmann-Therapie Systeme Ag Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system
US6287693B1 (en) * 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
DK2316439T3 (en) * 2001-05-01 2015-08-10 Euro Celtique Sa Abuse-proof transdermal systems containing opioids
US6913760B2 (en) * 2001-08-06 2005-07-05 New England Medical Hospitals, Inc. Drug delivery composition
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
CA2496454A1 (en) * 2002-04-23 2003-11-06 Alza Corporation Transdermal analgesic systems with reduced abuse potential
JP4949625B2 (ja) * 2002-06-10 2012-06-13 ユーロ−セルティーク エス．エイ． 経皮送達デバイスに含有された活性薬剤の誤用を防止する、経皮送達デバイスの廃棄システム
PT1526848E (pt) * 2002-08-09 2007-08-08 Gruenenthal Gmbh Antagonistas dos receptores de opióides em sistemas transdérmicos contendo buprenorfina
EP1554290B1 (en) * 2002-10-25 2009-09-30 Euro-Celtique S.A. Analogs and prodrugs of buprenorphine
US7524515B2 (en) * 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
MXPA05009757A (es) * 2003-03-13 2005-12-05 Controlled Chemicals Inc Conjugados de oxicodona con menor potencial de abuso y duracion de accion extendida.
US20040191301A1 (en) * 2003-03-27 2004-09-30 Van Duren Albert Philip Transdermal device having a phase change material
US20080020028A1 (en) * 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
WO2005025549A2 (en) * 2003-09-10 2005-03-24 Noven Pharmaceuticals, Inc. Multi-layer transdermal drug delivery device
AU2004286852A1 (en) * 2003-10-30 2005-05-19 Alza Corporation Transdermal analgesic systems having reduced abuse potential
EP1718258B1 (en) * 2004-02-23 2009-03-25 Euro-Celtique S.A. Abuse resistance opioid transdermal delivery device
EP1928881A2 (en) * 2005-08-19 2008-06-11 Pharmacofore, Inc. Prodrugs of active agents
PT2135603E (pt) * 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
US9522188B2 (en) * 2005-12-13 2016-12-20 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
ES2549115T3 (es) * 2006-09-22 2015-10-23 Zynerba Pharmaceuticals, Inc. Profármacos de buprenorfina administrables por vía transdérmica y composiciones resistentes al consumo excesivo de los mismos

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4458376A4 (en) * 2022-01-30 2025-05-07 Zhejiang University PH-REACTIVE ANALGESIC FOR TARGETING DAMAGED DORSAL ROOT GANGLION SEGMENT AND USE THEREOF

Also Published As

Publication number Publication date
JP2011515495A (ja) 2011-05-19
MX2010010512A (es) 2010-11-09
WO2009120889A3 (en) 2011-01-20
WO2009120889A2 (en) 2009-10-01
EP2254561A2 (en) 2010-12-01
US20090246265A1 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
US20090246265A1 (en) Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
CA2795158C (en) Abuse-deterrent transdermal formulations of opiate agonists and agonist-antagonists
CA2795156C (en) Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs
CA2955247C (en) Abuse deterrent opiod/opiod-antagonist transdermal patch
US8309568B2 (en) Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs
CA2679316C (en) Morphine composition for transdermal absorption, morphine composition storing unit and transdermal absorption preparation using the same
KR100742471B1 (ko) 활성 물질 디아모르핀을 포함하는 약학 제제 및 아편제중독증의 치료 방법에서의 그의 용도
US20190328681A1 (en) Transdermal patch
CA2699172A1 (en) Compositions and methods for delivery of poorly soluble drugs
CZ20023030A3 (cs) Farmaceutický prostředek
JPH04128231A (ja) ブプレノルフインを経皮的にデリバーすることからなるコ力インおよびヘロイン耽溺の治療方法
US10874658B2 (en) Sublingual opioid formulations containing naloxone

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20150326